inavolisib Itovebi
Selected indexed studies
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. (N Engl J Med, 2024) [PMID:39476340]
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. (N Engl J Med, 2025) [PMID:40454641]
- Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. (J Med Chem, 2022) [PMID:36455032]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. (2025) pubmed
- Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. (2024) pubmed
- Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. (2024) pubmed
- Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. (2025) pubmed
- Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. (2022) pubmed
- Inavolisib: First Approval. (2025) pubmed
- PMID:41533822 (2025) pubmed
- RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy. (2022) pubmed
- Inavolisib (Itovebi) for locally advanced or metastatic breast cancer. (2024) pubmed
- Inavolisib. (2012) pubmed